BioSpace News Archive

Olink Holding AB announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research.

Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, announced completion of a multi-center clinical study which evaluated OCM™ Wound Matrix in the treatment of a variety of chronic non-healing wounds/ulcers.

Permira, the global investment firm, and PharmaCord LLC, a leading provider of patient services for the pharmaceutical industry, announced that a company backed by the Permira funds has signed a definitive agreement to make a substantial investment in PharmaCord.

Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program.

Domain Therapeutics today announces the publication of three international PCT patent applications.

Gilead Sciences, Inc. announced data from the Phase 2b MYR204 open-label study assessing the efficacy and safety of the first-in-class entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a, in adults living with compensated chronic hepatitis delta virus infection.

Zura Bio Limited, a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, announced the formation of a Scientific Advisory Board with leading experts from rheumatology, dermatology, and immunology.

Pluri Inc., a leading biotechnology company that transforms cells into solutions, announced the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has exercised its option for year two of the three-year $4.2 million contract it entered into with Pluri in July 2023.

Replimune Group, Inc. today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma.

Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. successfully completed the Phase I clinical trial of its self-developed new injectable polymyxin antibacterial drug MRX-8 in China, achieving the expected goals.